GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: GA-101 | GA101 | Gazyva®
obinutuzumab is an approved drug (FDA (2013), EMA (2014))
Compound class:
Antibody
Comment: Obinutuzumab is a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb. Prior to 2009 obinutuzumab was known as afutuzumab.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. View more information in the IUPHAR Pharmacology Education Project: obinutuzumab |
Classification ![]() |
|
| Compound class | Antibody |
| Approved drug? | Yes. EU EMA (2014) | US FDA (2013) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 9043 | obinutuzumab |
Synonyms ![]() |
| GA-101 | GA101 | Gazyva® |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 238 |
| Other databases | |
| GtoPdb PubChem SID | 178103523 |
| PubChem SID | 178103523 |
| Search PubMed clinical trials | obinutuzumab |
| Search PubMed titles | obinutuzumab |
| Search PubMed titles/abstracts | obinutuzumab |
| Wikipedia | Obinutuzumab |